HealthCare Global Enterprises Sells Fertility Unit for ₹37.64 Crore

Key Financials for FY26

• Consolidated Profit After Tax: ₹2,278 Lakhs
• Standalone Profit After Tax: ₹1,458 Lakhs

Reader Takeaway: The divestment of a non-core asset, combined with strong FY26 profits, highlights HCG's strategic focus and financial health.

Divestment of BACC Health Care Approved

HealthCare Global Enterprises Limited (HCG) announced that its Board of Directors has approved the sale of its entire shareholding in BACC Health Care Private Limited. The transaction is valued at ₹37.64 crore. This decision was made alongside the release of the company's audited financial results for the fiscal year ending March 31, 2026.

Strategic Shift to Oncology Focus

The sale of BACC Health Care, which operates in fertility and reproductive healthcare and is not a material subsidiary, signals HCG's strategic intention to concentrate on its core oncology business. The FY26 financial results offer shareholders a clear view of the company's performance, with a consolidated profit after tax reported at ₹22.78 crore.

Streamlining Operations for Growth

HCG has been strengthening its position in the oncology sector. The divestment of BACC Health Care aligns with a strategy to streamline operations and focus resources on areas where HCG possesses a significant competitive advantage. The company's financial performance in FY26 reflects its operational efficiency.

Management Changes and Future Outlook

Following the divestment, HCG will no longer hold any stake in BACC Health Care. The company has also approved several key personnel changes. These include the re-appointment of directors and the appointment of a new Chief Financial Officer (CFO) and Assistant Vice President of Investor Relations, with these changes expected to take effect in late May 2026. These appointments are intended to strengthen the management team.

Key Risks for Investors

Investors will be watching for the successful completion of the divestment process. Additionally, the smooth transition of key leadership roles and their impact on the company's future strategic execution will be crucial factors to monitor.

Industry Context

While specific peer financial data for FY26 is not detailed here, HCG's dedicated focus on oncology distinguishes it within the broader healthcare services sector. Companies frequently divest non-core assets to improve profitability and sharpen their focus on primary revenue streams.

Performance Metrics for FY26

For the fiscal year ended March 31, 2026:

• Consolidated Revenue: ₹2,538.43 crore
• Consolidated Profit After Tax: ₹22.78 crore
• Standalone Revenue: ₹1,359.37 crore
• Standalone Profit After Tax: ₹14.58 crore

Next Steps for Investors

Investors should closely track the finalization of the BACC Health Care divestment. Furthermore, the performance of the company under its newly appointed key personnel and its continued growth in the oncology segment will be important areas to watch.